We are excited to share with you our Nature in Biomedical Engineering article on the multi-parametric evaluation of a novel nano-immunotherapy scheme targeting atherosclerosis disease. The proposed methodology moderates CD40–CD40 ligand signalling in monocytes and macrophages of atherosclerotic plaques by blocking the interaction between CD40 and tumor necrosis factor receptor-associated factor 6 (TRAF6).

The accumulation of monocytes and macrophages in atherosclerosis has been associated with destabilization and rupture of plaque which can lead to acute cardiac events. Therefore, intervening in macrophage dynamics can be an efficacious therapeutic strategy in cardiovascular diseases. Indeed, our study demonstrated that a 1-week treatment regimen achieved significant anti-inflammatory effects in mice and non-human primates, due to the impaired migration capacity of monocytes.

We are very proud to have actively participated in this wonderful journey together with more than 30 researchers in 11 departments, across three countries. If you are interested in further details, please have a look at Dr Lameijer’s news article or read our original manuscript.

Thank you!